A Xarelto cerebral bleeding lawsuit has been filed by a woman who suffered the brain bleed just days after starting the blood thinner.
Karen N. was prescribed Xarelto (rivaroxaban) and began using it on June 16, 2017. She took the anticoagulant through June 20, 2017, which is when she experienced cerebral bleeding.
Xarelto is a product of pharmaceutical giants Johnson & Johnson, Janssen and Bayer. Known as one of the New Oral Anticoagulants (NOACs), Xarelto has been advertised as a breakthrough blood-thinning drug designed to replace warfarin (Coumadin), an established drug used to prevent stroke and systemic embolism for the past 60 years.
Warfarin has faced criticism because a patient’s blood must be monitored with periodic testing to ensure a therapeutic level is maintained. Users also face some dietary restrictions and must adhere to a twice daily dose. However, in the event of an injury or accident, the blood clotting effects of warfarin can be halted with an IV dose of vitamin K. No such antidote for Xarelto’s clotting inhibition exists.
According to the cerebral bleeding lawsuit,…